日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Nitrogen excretion from beef cattle fed a wide range of diets compiled in an intercontinental dataset: a meta-analysis

一项基于洲际数据集的荟萃分析，研究了饲喂各种不同日粮的肉牛的氮排泄情况。

期刊:Journal of Animal Science
影响因子:2.9
doi:10.1093/jas/skac150
Bougouin, Adeline; Hristov, Alexander; Zanetti, Diego; Filho, Sebastiao C V; Rennó, Lucianna N; Menezes, Ana C B; Silva, Jarbas M; Alhadas, Herlon M; Mariz, Lays D S; Prados, Laura F; Beauchemin, Karen A; McAllister, Tim; Yang, WenZhu Z; Koenig, Karen M; Goossens, Karen; Yan, Tianhai; Noziere, Pierre; Jonker, Arjan; Kebreab, Ermias
发表日期：2022
文献求助 收藏

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

来自中国、巴西和韩国的类风湿性关节炎患者，对常规治疗反应不佳，使用乌帕替尼治疗。

期刊:International Journal of Rheumatic Diseases
影响因子:2
doi:10.1111/1756-185X.14235
Zeng, Xiaofeng; Zhao, Dongbao; Radominski, Sebastiao C; Keiserman, Mauro; Lee, Chang K; Meerwein, Sebastian; Enejosa, Jeffrey; Sui, Yunxia; Mohamed, Mohamed-Eslam F; Park, Won
关节炎
发表日期：2021
文献求助 收藏

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

英夫利昔单抗 (IFX) 生物类似药 PF-06438179/GP1111 在类风湿性关节炎患者中长期疗效、安全性和免疫原性评估（从参考 IFX 转换或继续接受生物类似药治疗）：一项随机、双盲、III 期试验的第 54-78 周数据

期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-019-00403-z
Cohen, Stanley B; Radominski, Sebastiao C; Kameda, Hideto; Kivitz, Alan J; Tee, Michael; Cronenberger, Carol; Zhang, Min; Hackley, Sarah; Rehman, Muhammad I; von Richter, Oliver; Alten, Rieke
关节炎
免疫/内分泌
发表日期：2020
文献求助 收藏

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis

PF-06438179/GP1111（一种英夫利昔单抗生物类似药）与参考英夫利昔单抗在中重度活动性类风湿关节炎患者中的比较研究：亚组分析

期刊:International Journal of Rheumatic Diseases
影响因子:2
doi:10.1111/1756-185X.13846
Kameda, Hideto; Uechi, Eishi; Atsumi, Tatsuya; Abud-Mendoza, Carlos; Kamei, Kazumasa; Matsumoto, Tsugumi; Ponce de Leon, Dario; Rehman, Muhammad I; Zhang, Min; Radominski, Sebastiao C
关节炎
发表日期：2020
文献求助 收藏

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

一项随机、双盲、III期研究比较了英夫利昔单抗生物类似药PF-06438179/GP1111与参考英夫利昔单抗：从第30周到第54周的疗效、安全性和免疫原性。

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2018-000876
Alten, Rieke; Batko, Bogdan; Hala, Tomas; Kameda, Hideto; Radominski, Sebastiao C; Tseluyko, Vira; Babic, Goran; Cronenberger, Carol; Hackley, Sarah; Rehman, Muhammad; von Richter, Oliver; Zhang, Min; Cohen, Stanley
免疫/内分泌
发表日期：2019
文献求助 收藏

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

一项随机对照试验比较了PF-06438179/GP1111（一种英夫利昔单抗生物类似药）和英夫利昔单抗参考产品治疗甲氨蝶呤治疗无效的中重度活动性类风湿关节炎的疗效。

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-018-1646-4
Cohen, Stanley B; Alten, Rieke; Kameda, Hideto; Hala, Tomas; Radominski, Sebastiao C; Rehman, Muhammad I; Palaparthy, Ramesh; Schumacher, Karl; Schmitt, Susanne; Hua, Steven Y; Ianos, Claudia; Sewell, K Lea
关节炎
发表日期：2018
文献求助 收藏